• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Archives»Medical Devices & Diagnostics (Page 2)

Why Cornerstone Robotics’ Sentire CE Mark could shake up Europe’s surgical robotics market

By Pallavi Madhiraju on May 25, 2026   Medical Devices & Diagnostics  

Why Cornerstone Robotics’ Sentire CE Mark could shake up Europe’s surgical robotics market

Cornerstone Robotics has cleared Europe’s MDR bar for Sentire. The real test is whether surgical robotics can scale beyond elite hospitals.

A stool test may be the next wellness battleground. Resbiotic and Tiny Health want in early

By Pallavi Madhiraju on May 25, 2026   Medical Devices & Diagnostics  

A stool test may be the next wellness battleground. Resbiotic and Tiny Health want in early

Find out how Resbiotic and Tiny Health’s at-home microbiome test could reshape consumer gut health, diagnostics and personalised wellness.

Can Elmach’s WKH-100 cartoner help pharma manufacturers rethink compact packaging automation?

By Pallavi Madhiraju on May 25, 2026   Medical Devices & Diagnostics  

Can Elmach’s WKH-100 cartoner help pharma manufacturers rethink compact packaging automation?

Find out how Elmach’s WKH-100 cartoner could improve flexible, GMP-ready pharma packaging for bottles, blisters and tubes.

Why Basler’s embedded vision system matters for next-generation laboratory automation

By Pallavi Madhiraju on May 24, 2026   Medical Devices & Diagnostics  

Why Basler’s embedded vision system matters for next-generation laboratory automation

Find out how Basler’s GMSL vision system could improve lab automation, imaging workflows, and data handling in life sciences.

GHO Capital and CBC Group deal signals a bigger private capital push into life sciences

By Pallavi Madhiraju on May 24, 2026   Medical Devices & Diagnostics  

GHO Capital and CBC Group deal signals a bigger private capital push into life sciences

GHO Capital and CBC Group are creating a $21bn healthcare investor. Find out what it means for pharma, medtech and life sciences funding.

Can Europe contain its STI surge before antimicrobial resistance narrows treatment options?

By Pallavi Madhiraju on May 24, 2026   Medical Devices & Diagnostics  

Can Europe contain its STI surge before antimicrobial resistance narrows treatment options?

Europe’s STI surge is testing diagnostics, prevention and treatment capacity as gonorrhoea and syphilis reach record levels.

Veracyte’s ASCO 2026 data could sharpen the commercial case for genomic cancer diagnostics

By Pallavi Madhiraju on May 23, 2026   Medical Devices & Diagnostics  

Veracyte’s ASCO 2026 data could sharpen the commercial case for genomic cancer diagnostics

Veracyte’s ASCO data could sharpen the case for genomic testing in breast and prostate cancer. Read why adoption still faces hard tests.

ClearNote Health targets early pancreatic cancer detection with multi-analyte blood test data

By Pallavi Madhiraju on May 23, 2026   Medical Devices & Diagnostics  

ClearNote Health targets early pancreatic cancer detection with multi-analyte blood test data

ClearNote Health will present Avantect pancreatic cancer test validation data at ASCO 2026. Find out what it could mean for early detection.

Portable MRI in emergency departments: What Hyperfine’s PRIME data changes

By Pallavi Madhiraju on May 23, 2026   Medical Devices & Diagnostics  

Portable MRI in emergency departments: What Hyperfine’s PRIME data changes

Find out how Hyperfine’s PRIME study could reshape emergency brain imaging with faster bedside portable MRI access.

Can Inocras’ whole-genome HRD data change how ovarian cancer patients are selected for PARP maintenance?

By Pallavi Madhiraju on May 23, 2026   Medical Devices & Diagnostics  

Can Inocras’ whole-genome HRD data change how ovarian cancer patients are selected for PARP maintenance?

PARP selection still leaves gaps. Inocras’ WGS-HRD data suggest whole-genome testing may refine ovarian cancer maintenance decisions.

« Previous 1 2 3 4 … 42 Next »

Recent Posts

  • Can Convergent Therapeutics define the next prostate cancer standard after Lu-PSMA therapy?
  • Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing
  • Is Amgen’s bispecific lung cancer drug becoming a global standard after chemotherapy failure?
  • Fulgent Genetics’ oncology pivot gets sharper as FID-007 shows Phase 2 activity at ASCO 2026
  • Minghui and Qilu push MHB088C forward as prostate cancer ADC race tightens
  • Why Aphranel’s EU MDR approval could sharpen competition in CaHA dermal fillers
  • Oricell’s ASCO 2026 liver cancer data put GPC3 CAR-T back in the spotlight
  • Can Lilly turn Hanmi’s sonefpeglutide into the next long-acting GLP-2 rare disease bet?
  • Can enicepatide and petrelintide help Genentech build a differentiated obesity franchise?
  • Can Summit and Akeso turn ivonescimab into a global lung cancer challenger?
  • Why Tempus AI’s Lens upgrade matters for precision oncology drug development
  • Is Pfizer’s Braftovi regimen becoming the new benchmark for BRAF-mutant colorectal cancer?
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes